#1 Clinical Trials Search in Europe

Cyclophosphamide

Cyclophosphamide is a powerful medication used in clinical trials to treat various conditions, including cancer and autoimmune diseases. This article explores recent clinical trials investigating the use of cyclophosphamide in different medical contexts, highlighting its potential benefits and applications.

Table of Contents

What is Cyclophosphamide?

Cyclophosphamide is a powerful medication used in the treatment of various cancers and autoimmune disorders. It belongs to a class of drugs known as alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from dividing and growing[1]. Cyclophosphamide is also known by its brand names Cytoxan® and Neosar®[2].

Conditions Treated with Cyclophosphamide

Cyclophosphamide is used to treat a wide range of conditions, including:

  • Various types of cancer: Such as breast cancer, colorectal cancer, and lymphomas[3][4]
  • Blood disorders: Including leukemias and myelodysplastic syndromes[2]
  • Autoimmune disorders: Such as membranous nephropathy (a kidney disorder)[5]
  • Preparation for stem cell transplantation: Used in conditioning regimens before transplant procedures[2]

How Cyclophosphamide Works

Cyclophosphamide works by damaging the DNA of rapidly dividing cells, such as cancer cells. This damage prevents the cells from reproducing and ultimately leads to their death. While it primarily targets cancer cells, it can also affect other fast-growing cells in the body, which is why it may cause side effects[1].

In autoimmune disorders, cyclophosphamide suppresses the immune system, helping to reduce inflammation and prevent the body from attacking its own tissues[5].

How Cyclophosphamide is Administered

Cyclophosphamide can be administered in several ways, depending on the condition being treated and the specific treatment plan:

  • Oral tablets: Taken by mouth, often daily or on specific days of a treatment cycle[4]
  • Intravenous (IV) infusion: Given through a vein, typically in a hospital or clinic setting[1]
  • Different dosing schedules: Can be given in high doses less frequently, or in lower doses more frequently (known as metronomic dosing)[6]

The dosage and schedule of cyclophosphamide can vary greatly depending on the specific condition being treated and the individual patient’s needs.

Cyclophosphamide in Clinical Trials

Cyclophosphamide is being studied in various clinical trials to explore its effectiveness in different treatment regimens and conditions. Some notable areas of research include:

  • Combination therapies: Cyclophosphamide is often studied in combination with other drugs to enhance treatment effectiveness. For example, it’s being tested with drugs like bevacizumab for colorectal cancer[1].
  • Metronomic chemotherapy: This approach involves giving lower doses of cyclophosphamide more frequently, which may have different effects on cancer growth and blood vessel formation[4].
  • Stem cell transplantation: Cyclophosphamide is being studied as part of conditioning regimens before stem cell transplants and as a way to prevent graft-versus-host disease after transplantation[2].
  • Autoimmune disorders: Research is ongoing to compare cyclophosphamide with newer treatments for conditions like membranous nephropathy[5].

Potential Side Effects

Like all powerful medications, cyclophosphamide can cause side effects. Some potential side effects include:

  • Nausea and vomiting
  • Hair loss
  • Increased risk of infections due to lowered white blood cell counts
  • Fatigue
  • Changes in menstrual cycles or fertility
  • Bladder irritation

It’s important to note that not everyone experiences these side effects, and many can be managed with proper medical care. Your healthcare team will monitor you closely during treatment and can help address any side effects that may occur[3].

Condition Trial Description Cyclophosphamide Use
Multiple Myeloma Phase 1 and 2 study of lenalidomide, cyclophosphamide, and prednisone (REP) in relapsed/refractory multiple myeloma Combined with lenalidomide and prednisone
Breast Cancer Randomized trial evaluating neoadjuvant chemotherapy customized by BRCA1 levels in HER2-negative breast cancer Part of standard FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide) regimen
Lupus Nephritis Comparison of cyclophosphamide vs baricitinib for induction of remission in active lupus nephritis Intravenous cyclophosphamide 0.7mg/m2 every month
Lupus Nephritis Pharmacoeconomic study comparing cyclophosphamide vs mycophenolate mofetil as induction therapy Compared to mycophenolate mofetil for cost-effectiveness and clinical outcomes

FAQ

  • What is cyclophosphamide? Cyclophosphamide is a chemotherapy drug that belongs to the class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells and suppressing the immune system.
  • In which conditions is cyclophosphamide being studied? Based on the clinical trials data, cyclophosphamide is being studied in multiple myeloma, breast cancer, and lupus nephritis.
  • How is cyclophosphamide administered in these trials? Cyclophosphamide can be administered in different ways depending on the trial. It may be given intravenously (IV) or orally, and the dosage and frequency can vary based on the specific treatment protocol.
  • What are some potential side effects of cyclophosphamide? While specific side effects are not mentioned in the provided data, cyclophosphamide can cause various side effects including nausea, hair loss, and increased risk of infections. The trials monitor patients for adverse events and toxicities.
  • Is cyclophosphamide used alone or in combination with other drugs? In many of the trials mentioned, cyclophosphamide is used in combination with other drugs. For example, it's combined with lenalidomide and prednisone in multiple myeloma, and with other chemotherapy drugs in breast cancer treatments.

Ongoing Clinical Trials on Cyclophosphamide

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Germany

  • Study of pembrolizumab with drug combination for first-line treatment in patients with advanced-stage classic Hodgkin lymphoma

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +11

  • A study comparing AZD0486 after reduced chemotherapy versus standard chemotherapy in older or unfit patients with newly diagnosed large B-cell lymphoma

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland

  • A study comparing odronextamab combined with chemotherapy versus rituximab combined with chemotherapy in adults with previously untreated follicular lymphoma

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +2

  • Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +3

  • Testing avacopan added to standard treatment in patients with ANCA-associated vasculitis with severe kidney damage

    Recruiting

    3 1 1
    Investigated drugs:
    France

  • Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland

  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease

    Recruiting

    2 1 1 1
    Investigated drugs:
    Bulgaria France Germany Italy Poland Portugal +2

Glossary

  • Allogeneic hematopoietic transplantation: A procedure where a person receives blood-forming stem cells from a genetically similar, but not identical, donor. This is often used to treat certain blood and immune system disorders.
  • Neoadjuvant chemotherapy: Chemotherapy given before surgery to shrink tumors and make them easier to remove.
  • BRCA1: A gene that normally helps to suppress cell growth. When mutated, it can increase the risk of certain cancers, particularly breast and ovarian cancer.
  • Lupus nephritis: A kidney inflammation caused by systemic lupus erythematosus (SLE), an autoimmune disease.
  • Induction therapy: The first phase of treatment for a disease, aimed at inducing a remission.
  • Mycophenolate mofetil: An immunosuppressant drug used to prevent rejection in organ transplantation and to treat some autoimmune diseases.
  • Pharmacoeconomic analysis: A method to evaluate the cost and effects of pharmaceutical products and services.

References

  1. https://clinicaltrials.gov/study/NCT02271464
  2. https://clinicaltrials.gov/study/NCT04473911
  3. https://clinicaltrials.gov/study/NCT00055679
  4. https://clinicaltrials.gov/study/NCT02280694
  5. https://clinicaltrials.gov/study/NCT01955187
  6. https://clinicaltrials.gov/study/NCT00542191